Clotting drug linked to fewer blood transfusions in joint surgery

August 12, 2014

Giving the clotting drug tranexamic acid to patients undergoing joint replacement surgery can reduce the need for blood transfusions while not increasing the risk of complications, finds a study published in the BMJ today.

Tranexamic acid has been shown to reduce during or shortly after major joint surgery (the perioperative stage). However, safety concerns remain because large scale effectiveness studies are lacking.

In the USA, over 1 million hip and knee replacements are performed each year. In England and Wales the figure is about 180,000.

So a team of US researchers, led by Dr Stavros Memtsoudis at Hospital for Special Surgery, Weill Cornell Medical College, and Dr Jashvant Poeran at Mount Sinai School of Medicine, both in New York, set out to determine the effectiveness and safety of tranexamic acid in a large sample of US patients undergoing total hip or .

Using data from a national database, their study sample consisted of 872,416 total hip or knee replacement procedures at 510 US hospitals between 2006 and 2012.

After adjusting for factors such as patient age, sex, hospital size and location, type of procedure and anaesthesia used, patients given tranexamic acid (1000 mg, 2000 mg or 3000 mg) on the day of surgery were compared with patients not given the drug.

They found that use of tranexamic acid was significantly associated with an up to 69% reduction in the need for blood transfusions and was not associated with an increased risk of complications, including serious blood clots and acute kidney failure.

A dose of 2000 mg tranexamic acid appeared to have the best effectiveness and safety profile.

The research team also found use of tranexamic acid to be associated with lower rates of admission to an intensive care unit (ICU), lower length of hospital stay, and lower costs of hospital stay.

The authors say that tranexamic acid "was effective in reducing the need for blood transfusions while not increasing the risk of complications, including thromboembolic events and renal failure."

They acknowledge that their study has some limitations, but say "the prudent identification of patients most likely to benefit from tranexamic acid – that is those at increased risk of bleeding and for requiring blood transfusions - is warranted."

And they conclude that "additional studies focusing not only on subgroup specific effectiveness and safety but also on optimal dosing schemes are needed."

In an accompanying editorial, researchers at the London School of Hygiene and Tropical Medicine welcome today's study, but say it would be "premature to recommend the routine use of in general and orthopaedic surgery."

They point out some existing uncertainty over the risk of vascular complications and call for "an adequately powered randomised controlled trial" to resolve this.

Explore further: Hundreds more bleeding trauma patients could be saved if tranexamic acid was used more widely

More information: BMJ, www.bmj.com/cgi/doi/10.1136/bmj.g4934

Related Stories

Recommended for you

International study proves old blood is as good as new

October 24, 2016

It's been long thought that when blood transfusions are needed, it may be best to use the freshest blood, but McMaster University researchers have led a large international study proving that it is not so.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.